JAMES R SULAT
CIK 1229448 · Former CEO & CFO · last filed 2023-11-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$8.82M
Companies
6
Total Filings
53
Lifetime Open-Market Net
$254.5K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Keenova Therapeutics plc (MNK) Delisted | Director | 79,399 | $0.34 | $27.0K | $254.5K | 5 | 2023-06-29 |
| XCUR | Director | — | $1.76 | — | $0 | 3 | 2022-06-15 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Director | 0 | — | — | $0 | 7 | 2020-11-17 |
| MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Director | 54,090 | — | — | $0 | 17 | 2019-06-21 |
| CDXS | Director | 5,957,108 | $1.48 | $8.82M | $0 | 1 | 2010-04-29 |
| MEMY | President & CEO | 0 | $17.25 | $0 | $0 | 4 | 2009-01-05 |
Recent Filings · Page 2 of 6
53 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-17 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Disp (D) | −35,090 | $0 | EDGAR |
| 2020-06-23 | — | Mixed | +454,546 | $37.19B | |
| 2020-06-04 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Grant (A) | +10,269 | $0 | EDGAR |
| 2019-12-23 | — | Grant (A) | — | $0 | |
| 2019-06-21 | MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Mixed | +4,356 | $0 | EDGAR |
| 2019-05-29 | MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Exer (M) | +10,000 | $88.5K | EDGAR |
| 2019-05-20 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Grant (A) | +8,116 | $0 | EDGAR |
| 2018-09-10 | MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Exer (M) | +13,500 | $199.7K | EDGAR |
| 2018-07-20 | — | Grant (A) | +110,000 | $0 | |
| 2018-07-18 | — | Exer (M) | +30,000 | $11.1K |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.